Human Blood Substitute

About NanoGroup

NanoGroup is a publicly traded Polish biotech firm developing a diversified pipeline based on two core nanotechnology platforms: the NanOX system for organ preservation and transport of respiratory gases, and polysaccharide nanoparticle conjugates for targeted oncology. The company is in a pre-revenue, pre-clinical stage, actively raising capital and progressing multiple programs toward key 2026/2027 milestones. Its strategy involves building a group of subsidiaries (NanoSanguis, NanoVelos) to advance its platforms while also making strategic investments, such as in Auxilius Pharma's cardiovascular drug program.

Therapeutic Areas